Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity
Muriel Aguilar-Bretones, … , Marion P.G. Koopmans, Gijsbert P. van Nierop
Muriel Aguilar-Bretones, … , Marion P.G. Koopmans, Gijsbert P. van Nierop
Published January 3, 2023
Citation Information: J Clin Invest. 2023;133(1):e162192. https://doi.org/10.1172/JCI162192.
View: Text | PDF
Review

Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity

  • Text
  • PDF
Abstract

Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and vaccinations targeting the spike protein (S) offer protective immunity against coronavirus disease 2019 (COVID-19). This immunity may further be shaped by cross-reactivity with common cold coronaviruses. Mutations arising in S that are associated with altered intrinsic virus properties and immune escape result in the continued circulation of SARS-CoV-2 variants. Potentially, vaccine updates will be required to protect against future variants of concern, as for influenza. To offer potent protection against future variants, these second-generation vaccines may need to redirect immunity to epitopes associated with immune escape and not merely boost immunity toward conserved domains in preimmune individuals. For influenza, efficacy of repeated vaccination is hampered by original antigenic sin, an attribute of immune memory that leads to greater induction of antibodies specific to the first-encountered variant of an immunogen compared with subsequent variants. In this Review, recent findings on original antigenic sin are discussed in the context of SARS-CoV-2 evolution. Unanswered questions and future directions are highlighted, with an emphasis on the impact on disease outcome and vaccine design.

Authors

Muriel Aguilar-Bretones, Ron A.M. Fouchier, Marion P.G. Koopmans, Gijsbert P. van Nierop

×

Figure 3

Model to correlate antigenic distance between SARS-CoV-2 variants with vaccine failure.

Options: View larger image (or click on image) Download as PowerPoint
Model to correlate antigenic distance between SARS-CoV-2 variants with v...
(A) An individual’s signature history of exposure to SARS-CoV-2 infection and vaccination determines the level of protection from infection. Model sera are collected early (samples 1–3) and late (samples 4–6) after full vaccination and after breakthrough infection with Omicron BA.2 (sample 7, red circle). (B) Antigenic cartography of SARS-CoV-2 shows the antigenic distance between variants (map adapted with permission from ref. 69). (C) The antibody landscape shortly after first, second, and third vaccination defines the magnitude and breadth of immune protection against SARS-CoV-2 variants (samples 1–3 from A) based on the antigenic distance from the vaccine strain that is inferred from the antigenic map. (D) At a later time point, waning antibody titers (samples 4–6 from A) may result in poor protection from antigenically distant strains. Breakthrough infection with Omicron BA.2 (sample 7) boosts the memory vaccine response and initiates a new type-specific response (red). The dashed lines in B represent the immune protection threshold after vaccination or breakthrough infection based on the later antibody landscapes from samples 4–7 that are modeled in C and D.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts